NCE-1 Intelligence & Market Opportunity

Tepmetko

Tepotinib

Anticancer

Oral Tablet

Approval Date

02-Mar-21

NCE-1 Date

02-Mar-25

NCE Date

02-Mar-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

137

2027

142

2028

149

2029

157

2030

165

2031

105

2032

Molecule profile

Details & specifications

Molecule

Tepotinib

Innovator

EMD SERONO, INC.

Dosage Form

Oral Tablet

Strength

EQ 225 mg base

Therapeutic Category

Anticancer

Usage

To treat non-small cell lung cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.